Antimicrobials
Valganciclovir

Valganciclovir

Restricted

N/A
Moderate (40 to 70%)

Dosing

General Information

Restricted: for use in HIV/AIDS, transplant, hematology, oncology, or ophthalmology patients.

FDA Treatment Recommendations: Cytomegalovirus infections.

CBC including platelet count and serum creatinine at baseline and periodically during therapy.

Monitoring more frequently in patients with renal impairment, previous drug-induced leukopenia and those with ANC less than 1 on treatment initiation.

  • Potential to cause birth defects in humans

  • Hypertension

  • Headache, insomnia

  • Diarrhea, nausea, vomiting and abdominal pain

  • Anemia, thrombocytopenia, neutropenia

  • Tremor

  • Retinal detachment

  • Increased serum creatinine

May increase levels of:

  • Amphotericin B

  • Imipenem

  • Mycophenolate

  • Tenofovir products

  • Zidovudine

Valganciclovir is a prodrug of ganciclovir with excellent bioavailability, equivalent to that of IV ganciclovir and much better than oral ganciclovir.